日益增长的心肌梗塞(MI)负担成为一个主要的全球健康问题,其导致全世界相当大的死亡率。因此,有必要开发一种副作用较小的心肌梗死新治疗方法。心脏肥大,氧化应激,炎症通路在MI的发病机制中起着至关重要的作用。这项研究建立了抗心脏肥大,抗氧化剂,抗炎,和巴伦烯的心肌梗死面积限制作用。用异丙肾上腺素(100毫克/千克体重)诱导大鼠心肌梗死,然后用瓦伦烯和心脏敏感标志物治疗,心脏肥大,氧化应激,炎症的标志,核因子-κB炎症通路,并估计/确定心肌梗死面积。血清心脏诊断标志物,心脏肥大,共轭二烯,炎症的标志,促炎细胞因子,异丙肾上腺素显著增加心肌梗死面积(P<0.05)。Further,心脏抗氧化酶和抗炎细胞因子基因显著降低(P<0.05)。2,3,5-三苯基氯化四唑染料染色显示梗死面积较大。此外,心肌梗死大鼠心脏组织的组织学结果显示心肌纤维分离,坏死,和炎症细胞。口服瓦伦烯(12mg/kg体重)治疗后,daily,两周来异丙肾上腺素诱导的心肌梗死大鼠逆转了上述所有结构,生物化学,分子,和组织学参数调查,通过其抗心脏肥大,抗氧化剂,抗炎,和心肌梗死面积限制效应。因此,瓦伦烯是抑制心脏肥大的潜在候选者,氧化应激,核因子-κB炎症通路,和心肌梗死面积,并在MI表现出心脏保护作用。
The growing burden of myocardial infarction (MI) becomes a major global health issue that is accountable for considerable mortality worldwide. Hence, it is obligatory to develop a new treatment for MI having lesser side effects. Cardiac hypertrophy, oxidative stress, and inflammatory pathways play crucial roles in the pathogenesis of MI. This investigation established the anti-cardiac hypertrophic, antioxidant, anti-inflammatory, and myocardial infarct size limiting effects of valencene. Rats were induced MI by isoproterenol (100 mg/kg body weight) and then treated with valencene and cardiac sensitive markers, cardiac hypertrophy, oxidative stress, markers of inflammation, nuclear factor- κB inflammatory pathway, and myocardial infarct size was estimated/determined. The serum cardiac diagnostic markers, cardiac hypertrophy, conjugated dienes, markers of inflammation, pro-inflammatory cytokines, and myocardial infarct size were significantly (P < 0.05) increased by isoproterenol. Further, antioxidant enzymes and anti-inflammatory cytokine gene were significantly (P < 0.05) decreased in the heart. The 2, 3, 5-triphenyl tetrazolium chloride dye staining revealed a larger infarct size. Moreover, histological results of myocardial infarcted rat\'s cardiac tissue revealed separation of cardiac muscle fibers, necrosis, and inflammatory cells. Post-treatment with valencene (12 mg/kg body weight) orally, daily, for two weeks to isoproterenol-induced myocardial infarcted rats reversed all above said structural, biochemical, molecular, and histological parameters investigated, by its anti-cardiac hypertrophic, antioxidant, anti-inflammatory, and myocardial infarct size limiting effects. Thus, valencene is a potential candidate for inhibiting cardiac hypertrophy, oxidative stress, nuclear factor- κB inflammatory pathway, and myocardial infarct size and exhibited cardioprotection in MI.